Drug Profile
GQ 303
Alternative Names: GQ-303Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator GeneQuine
- Developer GQ Bio Therapeutics
- Class Anti-inflammatories; Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Proteoglycan replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 01 Feb 2023 GQ 303 is still in preclinical trials for Osteoarthritis in Germany (GeneQuine Biotherapeutics pipeline, January 2023)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Osteoarthritis in Germany (Intra-articular, Injection)
- 02 Dec 2019 GeneQuine has patents pending for GQ 303 in USA